GlassScriptPhysician profile
Osman Malik
NPI 1912987652
$1,058.29
in general payments reported to CMS, 2019-2025
14 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $65.45 · 2021: $62.56 · 2024: $112 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.11 | 2019-2025 | Jascayd |
| Pulmonx Corporation | $160.75 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $141.65 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $138.60 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $78.06 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $70.57 | 2024-2025 | Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $68.94 | 2025 | Nucala, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $53.31 | 2020-2021 | |
| Genentech USA, INC. | $48.79 | 2019 | |
| Verona Pharma, INC. | $34.68 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $28.89 | 2020 | |
| Shionogi INC | $24.54 | 2025 | Fetroja |
| Genzyme Corporation | $21.91 | 2025 | |
| Grifols USA, LLC | $14.49 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.